Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years at the time of signing the informed consent form.~2. Able to adhere to the study visit schedule and other protocol requirements.~3. Untreated grade 1, 2, or 3a follicular non-Hodgkin's lymphoma.~4. At least one measurable lesion according to the International Working Group Criteria for Response, of greater that 1.5cm.~5. Eastern Cooperative Oncology Group (ECOG) performance status of \< 2 at study entry.~6. Laboratory test results within these ranges: Absolute neutrophil count \>/=1.5 x 10\^9/L; Platelet count \>/=100 x 10\^9/L; Serum creatinine \</= 2.0 mg/dL; Total bilirubin \</= 1.5 mg/dL; AST (SGOT) and ALT (SGPT) \</= 2 x upper limit of normal (ULN) or \</= 5 x ULN if hepatic metastases are present.~7. Disease free of prior malignancies for at least 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast.~8. Have a high risk FLIPI score, as defined by a FLIPI score \>/= 3.~9. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli-International unit (mIU)/mL within 10 to 14 days prior to study entry.~10. An ejection fraction of \>/= 50% as documented by a cardiac function study.~Exclusion Criteria:~1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.~2. Pregnant or breast feeding females.~3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.~4. Use of any prior chemotherapy for follicular lymphoma.~5. Known hypersensitivity to Bendamustine, mitoxantrone, or mannitol.~6. A history of congestive heart failure.~7. Any prior use of bendamustine or mitoxantrone.~8. Concurrent use of other anti-cancer agents or experimental treatments.~9. Known positive for HIV or infectious hepatitis type B or C.~10. Creatinine clearance less than 40 ml/min.~11. A known history of hepatic insufficiency (patients with a history of fulminate hepatic failure, hepatic encephalopathy, cirrhosis, and autoimmune hepatitis).~12. Any history of grade 3b follicular lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine + Mitoxantrone + Rituximab (Type: EXPERIMENTAL): Bendamustine starting dose 90 mg/m\^2 intravenously (IV) over 30-60 minutes on Days 1 and 2 of each 8-day cycle. Mitoxantrone 10 mg/m\^2 IV over 15 minutes on Day 2 of each cycle. Rituximab 375 mg/m\^2 IV over several hours on Day 1 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues